Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Open Access
- 22 January 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
Abstract
Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical success has increased interest in the role of B cells in the pathogenesis of MS and in ways to potentially improve upon current B cell therapies. In this mini review, we will critically review previous and ongoing clinical trials of anti-CD20 monoclonal antibodies in MS, including rituximab, ocrelizumab, ofatumumab, and ublituximab. Side effects and adverse event profiles will be discussed. Studies examining the proposed mechanisms of action of B cell depleting therapies will also be reviewed.Keywords
This publication has 48 references indexed in Scilit:
- Rituximab combination therapy in relapsing multiple sclerosisTherapeutic Advances in Neurological Disorders, 2012
- B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cellsThe Journal of Experimental Medicine, 2012
- Atacicept: targeting B cells in multiple sclerosisTherapeutic Advances in Neurological Disorders, 2010
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosisNeurology, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphomaAnnals of Oncology, 2010
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trialAnnals of Neurology, 2009
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti‐CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16British Journal of Haematology, 2008
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006